EGFR and non-small cell lung carcinoma: However, when Osimertinib was combined with Trametinib (MEK inhibitor), it displayed significantly enhanced potency, as evidenced by enhanced cleavage of caspase 3 and PARP (apoptotic markers) in EGFR-mutant NSCLC cells.